Dengue Vaccine Market Report 2022: Industry Growth, Competitive Analysis, Future Prospects Forecast To 2028

Precision Business Insights published a research report on research report "Dengue Vaccine market by Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, and Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, and Others), By End Users (Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs)) and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)- Global/Region/Country Forecast to 2028". Dengue vaccine market size was valued at US$ 362 million in the year 2021 and is anticipated to value at US$ 1196.48 Million by 2027 at a CAGR rate of 17.7% during the evaluation time span 2022-2028.

Glance our 200 slides market research and competitive intelligence research report, 25 Tables and 65 Figures and other qualitative sections with an in-depth TOC on "Dengue Vaccine market by Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, and Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, and Others), By End Users (Hospitals, Clinics, Government Institutes, and Non-Governmental Organizations (NGOs)) and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)- Global/Region/Country Forecast to 2028".

View detailed report description at https://precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/

Increase in the initiatives from WHO and local governments to restrain the dengue threat expected to boost the Dengue Vaccine Market demand
The incidence of dengue has become considerably over ongoing several years. A bigger part of the cases are asymptomatic, independent or gentle and therefore the genuine number of illnesses is remarkably under-announced. One displaying gauge demonstrates 390 million dengue infection diseases every year of which 96 million show clinically.

Virus serotypes cause dengue or breakbone fever, which are transmitted by Aedes aegypti mosquito to humans. It is epidemic in a number of countries of Latin America and Asia Pacific region. Increase in the global epidemic of dengue in above mentioned regions is projected to fuel the dengue vaccine demand over the evaluation time span. Growing initiatives from local governments and WHO to restrain the threat of dengue around the regions anticipated to fuel the demand for dengue vaccine market over the assessment tie span. Developing clinically effective vaccines in flexible dosing regimens predicted to impel the revenue growth of dengue vaccine market Furthermore, numerous governments are actively looking for integrating dengue vaccine in routine immunization programmers for preventing the dengue epidemics. Nearly 50 Mn dengue infections are there globally every year and dengue is prevalent in over 100 countries around the globe. At present, dengvaxia is the only vaccine available for the prevention of dengue in the marketplace. Dengvaxia (CYD-TDV) is a recombinant tetravalent vaccine administered in three doses in series of 0/3/6 month schedule.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=15690

Asia Pacific Dominates the Dengue Vaccine Market
Asia Pacific region anticipated to dominate the global dengue vaccines market due to the large population at the risk of dengue fever and the widespread occurrence and incidence of dengue fever. Latin America anticipated to witness highest market growth amid all other regions due o the early adoption of the vaccine in government immunization programs.

Competitive Analysis - Dengue Vaccine Market
There are a few major players operating in the dengue vaccine market, which include Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Insitituto Butantan(Brazil), Vabiotech (Vietnam), Panacea Biotech(India), Biological E (India), GlaxoSmithKline plc (U.K)and Merck & Co. Inc. (U.S.). These players aim at adopting a few effective strategies such as mergers, acquisitions and collaborations to strengthen their position in the market and increase the product portfolio. Key players are emphasizing on developing live and killed vaccines with better safety and efficacy to get larger revenue share in the global dengue vaccine market.

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.